Bufetico Join the waitlist
The basicsMethod

Every line checked out and it still went wrong: what a stock screener can't answer, from a Novo Nordisk town

Shaun Gamble felt the mood shift in Kalundborg, the Danish city where Novo Nordisk makes Wegovy, when Novo announced job cuts. What a stock screener can tell you about a company like that, and the four questions no column can answer.
21 September 2026 · · 6 min read

Your screener checked out on every line, and the thing that hurt you was never on the screen. Shaun Gamble felt the mood in town shift in September 2025. He owns a café that looks out over the harbor in Kalundborg, a small city on the Danish coast.

That was when Novo Nordisk, the company that makes Ozempic and Wegovy, said it would cut 9,000 jobs around the world, 5,000 of them in Denmark. Gamble knew a few of the people who were let go, and he told CNN in May 2026 that it was quite dramatic. Novo didn’t say how many of the cuts were in Kalundborg. Fewer than 17,000 people live there, and around 10,000 people work at Novo’s factory, counting employees and contractors, many of them from out of town. CNN says Novo has invested $9.3 billion in the area since 2021.

Years ago, Novo figured out that the drug in Ozempic, a diabetes medicine, also made people lose a lot of weight. So the Kalundborg factory started turning out Wegovy, which uses the same ingredient for weight loss. Danske Bank, the biggest bank in Denmark, credits Novo with keeping the country’s economy out of recession in 2023.

Martin Høgh Sørensen said people used to commute from Kalundborg to Copenhagen, and now it’s the other way around. Sørensen was 69 when CNN talked to him, and he’s lived there a long time. He works for Novo Nordisk Engineering, a company that’s helping expand the factory. CNN found him steering a sailboat off the harbor while his wife and two friends worked the ropes. Between the four of them, they’ve put in almost a hundred years at Novo or its sister company.

The mayor, Martin Damm, says more than a thousand homes are going up. He also says local builders and electricians have sometimes had trouble hiring, because many people would rather work at Novo. For Sørensen, the catch is the car mechanics. He said Novo has hired so many of them that it’s hard to get your car fixed.

What a screener would have seen

Novo’s annual report shows sales growing 25.0 percent in 2024, before slowing to 6.4 percent in 2025. The operating margin, what’s left of each Danish krone of sales after running the business, went from 44.2 percent to 41.3 percent. Most of that dip came from what Novo calls one-off restructuring costs.

A screener is built to catch numbers like those. It asks every company on its list the same simple question at once: does it have this or not? And it doesn’t get tired at company number twenty thousand. I built one. It puts every company through six layers, one for each measure, and you can narrow it down by exchange. Two of the layers tell you if a company is cheap or expensive, three tell you if it’s financially stable enough to take a hit, and one tells you if it’s still growing. But no screener can see behind a number. There are four questions no column can answer: whether a profit will happen again, whether an edge over rivals will last, whether growth came from the business itself or from buying other companies, and whether the people in charge are spending the money well. Novo ran into three of them in 2025 and 2026.

The edge and the factory

When a company keeps a steady margin for years, it usually has some edge over its rivals. The margin doesn’t tell you how long that edge will last. Novo’s edge came from getting there first. In 2025, Eli Lilly’s drugs in the same family as Ozempic and Wegovy outsold Novo’s in the US for the first time, according to the investment firm Jefferies. And the patent on semaglutide, the ingredient in both, ran out in 2026 in several countries, including China and India. Novo’s chief executive, Mike Doustdar, told CNN that as the first mover, Novo made mistakes its competitors got to learn from. None of that shows up in a margin. Neither does the good news on the other side: the pill version of Wegovy that Novo launched in the US in January 2026 passed five million prescriptions by August.

And then there’s the factory Sørensen’s company is helping expand. In 2021 Novo spent 6,335 million Danish kroner on property, plant and equipment, meaning its buildings and machines. In 2025, the year of the job cuts, it spent 60,140 million, more than nine times as much, mostly on more capacity to make its drugs. Whether that’s money well spent isn’t in any column, and nobody knows yet. A screener never meets the people who decide where the money goes. It only sees what they did once it shows up in the accounts, and by then the money is spent.

Where this breaks

In September 2026, I found out my model was reading the cash that moves through a bank as if it were the bank’s own, when most of it is other people’s money. So banks and almost every other financial company now get a gray square where the valuation would be. But gray only protects you from problems I’ve already found. That one showed up because sixty-seven financial companies had landed near the top of my list of the biggest gaps between price and value, when about nineteen would have been normal for their share of the list. If the same flaw had touched a handful of companies scattered through the list, nothing would have stood out.

And gray only kicks in when something is missing or broken. A profit with no money behind it gets caught on the cash line. But no column catches money that really did come in and may not come again. Take Tesla. Other carmakers pay it for regulatory credits they use to meet emissions rules, and that money comes in as cash like any other. Tesla’s own annual report says government action has already cut back some of those credit programs.

The café on the harbor

Gamble said that by spring, the feeling in town had settled down, and he hoped the layoffs had been a “glitch.” The day before CNN’s story ran, Novo reported its first quarter of 2026. On the income statement, the page most screeners read, the boom looked like it was back. Sales were up 24 percent from a year earlier, and operating profit was up 54 percent.

More than a quarter of those sales, 26,760 million kroner, was a single entry that Novo itself says won’t happen again. Since 2021, Novo had been holding back part of its US sales in case it owed discounts under 340B. That’s a federal program that makes drugmakers charge certain hospitals and clinics less. In January, a decision in a dispute over those discounts became final in Novo’s favor, and everything it was still holding back went into sales in one quarter. Novo says no cash came with it. The cash its operations brought in that quarter was a little less than a year before. Without that entry, sales fell 10 percent and operating profit fell 15 percent in kroner, or 4 and 6 percent at the exchange rates of a year earlier. Novo’s own headline that day went with the smaller profit.

Key factsThe numbers and where they come from · 21 September 2026
  • Novo Nordisk’s sales grew 25.0 percent in 2024 and 6.4 percent in 2025, and its operating margin went from 44.2 percent to 41.3 percent, mostly because of what Novo calls one-off restructuring costs (Novo’s annual report).
  • Spending on property, plant and equipment at Novo went from 6,335 million Danish kroner in 2021 to 60,140 million in 2025, mostly for more capacity to make its drugs, according to its annual reports.
  • In the first quarter of 2026, 26,760 million kroner of Novo’s sales was a single entry from a 340B discount dispute it won. Novo says the entry won’t happen again and that no cash came with it (Novo’s first-quarter report).
  • Without that entry, Novo reported, first-quarter sales fell 10 percent and operating profit 15 percent in kroner, or 4 percent and 6 percent at the exchange rates of a year earlier.

Bufetico puts every company on more than 30 exchanges through the same six layers. Prices update after every market close, and company financials once a month. What passes is decided by thresholds you set yourself. See it.

← All articles

Sold too early, or held on too long?

Join the waitlist and I'll email you when Bufetico opens, plus a new article or tool now and then.

No more than one email a week. You can unsubscribe anytime, and the Privacy Policy explains how we handle your name and email.

Can't tell a cheap stock from a dying one?

The Bufetico Filter checks more than 30,000 companies against six layers and shows you only the ones that pass. You decide how strict each layer is. Bufetico opens soon.

Join the waitlist »